The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Although infection by SARS-CoV-2, the causative agent of coronavirus pneumonia disease (COVID-19), is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, an existing drug used for disseminated intravasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Mizuki, Kiso, Maki, Sakai-Tagawa, Yuko, Iwatsuki-Horimoto, Kiyoko, Imai, Masaki, Takeda, Makoto, Kinoshita, Noriko, Ohmagari, Norio, Gohda, Jin, Semba, Kentaro, Matsuda, Zene, Kawaguchi, Yasushi, Kawaoka, Yoshihiro, Inoue, Jun-ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354595/
https://www.ncbi.nlm.nih.gov/pubmed/32532094
http://dx.doi.org/10.3390/v12060629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354595/
https://www.ncbi.nlm.nih.gov/pubmed/32532094
http://dx.doi.org/10.3390/v12060629

Ejemplares similares